Company Name
Chiral Quest (Suzhou) co.,ltd
Year of Establishment
2000
Annual Turnover(USD)
500,000 to 99,999,999
Company Introduction
Chiral Quest was founded in 2000, we provide chemical development and contract manufacturing services to meet demand at all stages of chemical development(kilo-lab, pilot-plant and commercial scale manufacture).
Chiral Quest has a manufacturing site in Jiangxi province (www.cqlonglife.cn), headquarters and R&D centre located in Suzhou Industrial Park; and three overseas offices located in USA, Europe and India. We have expertise in asymmetric hydrogenation, multi-step synthesis and cryogenic reactions. With 5 granted U.S. patents for asymmetric hydrogenation catalysts and 6 process patents for innovative routes to generic API intermediates.
Main Competitive Advantages
International Approvals/Standards,Experienced R&D Staff,Contract Manufacturing (CRO,CMO),Small Orders Accepted,Quality Service,
Other Competitive Advantages
CMO
Chiral Quest serves the global pharmaceutical industry with custom contract chemical development and manufacturing services, from preclinical development to commercial supply. We have a state-of-the-art R&D laboratory, equipped with modern analytical instruments, as well as a first class manufacturing facility. Chiral Quest has successfully developed more than 400 intermediates for Active Pharmaceutical Ingredients. Ranging from preclinical to phase III, with four intermediates being supplied for API’s approved by the FDA.We manufacture technology advantaged products from grams to metric ton scale.
Generic Drug Intermediates
Chiral Quest’s key technologies for asymmetric hydrogenation have been applied to innovative routes for the manufacture of generic drugs intermediates, on metric ton scale. For example, intermediates for Sitagliptin, Duloxetine, Aprepitant, Sacubitril and Lifesistat.
Milestone
2000: Founded by Professor Xumu Zhang in USA
2009: Chiral Quest pilot plant was established in Suzhou, Biobay
2009: Jiang Xi Long Life was founded by Dr. James Wu
2013: Chiral Quest acquired Longlife
2013: Filed a US DMF for Duloxetine,Sitagliptin Ints.
2015: Chinese Drug Manufacture Permit obtained
2016: New Workshop was opened in LongLife, capacity >400,000 L.
2016: Duns number : 544443599. FEI Number: 3012146143
2017: New drying workshop was put into service
2017: DMF filling for Sacubitril intermediate
2018: ISO 14001 and 18001 accreditations obtained
2018: USFDA audit approved